Industry News

Incyte Corporation today announced it has been ranked 4th on Forbes magazine’ s 2016 list of the World’ s Most Innovative Companies. Incyte, a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, is advancing an innovative and diverse portfolio of large and small molecules comprised of 14 development candidates against 11..."/>
Forbes Magazine Names Incyte to its List of World’s Most Innovative Companies for Second Consecutive Year
Mallinckrodt plc, a leading global specialty pharmaceutical company, today announced the U.S. Food and Drug Administration has granted the company's request for a Fast Track designation for its Investigational New Drug application for Synacthen ® Depot in the treatment of Duchenne muscular dystrophy. Synacthen Depot is a depot formulation of Synacthen, a synthetic 24 amino acid melanocortin receptor agonist."/>
Mallinckrodt Receives FDA Fast-Track Designation for Synacthen® Depot IND Application
Derma Sciences, Inc., a tissue regeneration company focused on advanced wound and burn care, announces the launch of new, MEDIHONEY ® Hydrogel Sheet Dressings and the receipt of Healthcare Common Procedural Coding System codes awarded on August 19, 2016 by the Centers for Medicare and Medicaid Services. Stephen T. Wills, Executive Chairman and Interim..."/>
Derma Sciences Receives Reimbursement Coding for New MEDIHONEY® Hydrogel Dressings
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced it has entered into a $12.5 million common stock purchase agreement with Aspire Capital Fund, LLC. Under the terms of the agreement, Aspire Capital has made an initial purchase of $500,000 of Viking common stock at $1.50 per share, which represents a 15% premium over the..."/>
Viking Therapeutics Enters Into $12.5 Million Common Stock Purchase Agreement with Aspire Capital
Bristol-Myers Squibb Co., AstraZeneca PLC, Eli Lilly and Co., and GlaxoSmithKline PLC. On Wednesday, August 17, 2016, Brean Capital downgraded the sector to "Underweight" on technical indicators such as deteriorating relative strength, price momentum, and momentum of breadth."/>
Drug Makers Stocks under Review -- Bristol-Myers Squibb, AstraZeneca, Eli Lilly, and GlaxoSmithKline
NeuroDerm Ltd., a clinical stage pharmaceutical company developing drugs for central nervous system diseases, today announced financial results for the second quarter ended June 30, 2016 and provided a corporate update.. “We have been very productive in recent months advancing our clinical programs and moving closer toward our goal of providing a less invasive, continuous levodopa delivery treatment option for patients suffering from..."/>
NeuroDerm Announces Second Quarter 2016 Financial Results and Provides Corporate Update
NeuroDerm Ltd., a clinical stage pharmaceutical company developing drugs for central nervous system disorders, today announced that it has initiated enrollment of Parkinson's disease patients in a Phase III efficacy trial of ND0612L, the company’ s low-dose continuous, subcutaneously delivered levodopa/carbidopa liquid formulation.. iNDiGO is a 16- week, international, multicenter, randomized, double-blind, placebo controlled, parallel group..."/>
NeuroDerm Initiates Patient Enrollment in a Phase III Trial of ND0612L for the Treatment of Parkinson’s Disease
Immunovaccine Inc., a clinical stage vaccine and immunotherapy company, today announced new data from its Phase 1/ 1 b trial in ovarian cancer, which reinforced previously reported results showing that DPX-Survivac was well tolerated, with no unexpected treatment-related serious adverse events and that it demonstrated the ability to generate a relevant, sustained immune response. New data from the Phase 1/ 1 b trial yielded positive findings on..."/>
Immunovaccine Announces Additional Positive Topline Results from Phase 1/1b Clinical Trial Program With DPX-Survivac in Ovarian Cancer
NeuroMetrix, Inc. announced today that Quell ® will be featured in the Target Open House in San Francisco. "We are delighted that Target has added Quell to their Open House concept," said Frank McGillin, SVP and General Manager, Consumer of NeuroMetrix. "Consumers are showing a tremendous interest in connected products, particularly around health and wellness."/>
NeuroMetrix Announces That Quell Will Be Featured in the Target Open House
NanoViricides, Inc., a global leader in nanomedicines that is developing biomimetic anti-viral drugs reports that Honorable U.S. Senator Chris Murphy visited the Company's new campus in Shelton, CT, on Wednesday, August 24th, 2016.. "NanoViricides is exactly the type of innovative company that is driving job creation throughout greater New Haven and the Naugatuck Valley," said Senator Murphy, adding, "I was incredibly impressed by the company..."/>
NanoViricides Reports on Senator Murphy's Visit to the Company's Shelton Campus
Sunesis Pharmaceuticals, Inc. today announced the publication of an article detailing the molecular and pharmacologic properties of vosaroxin as a new therapeutic for acute myeloid leukemia in the journal Drugs. The article, titled“ Molecular and Pharmacologic Properties of the Anticancer Quinolone Derivative Vosaroxin: A New Therapeutic for Acute Myeloid Leukemia,” is available online and will appear in the September 2016 print..."/>
Sunesis Announces Publication in "Drugs" Detailing Molecular and Pharmacologic Properties of Vosaroxin
EDAP TMS SA, the global leader in therapeutic ultrasound, announced today financial results for the second quarter and six months ended June 30, 2016, and provided an update on strategic and..."/>
EDAP Reports 69% Growth in HIFU Revenues and Operating Profit for First Half 2016
Shire plc, Aniston is encouraging people to make eye health a priority, and is raising awareness and understanding about Chronic Dry Eye symptoms, like the ones she experiences."/>
Shire and Jennifer Aniston Want to Inspire People to Show Their Eyes Some Love and Help Raise Awareness of Chronic Dry Eye
Biocon Ltd. announced today that the European Medicines Agency has accepted for review Mylan's Marketing Authorization Application for a proposed biosimilar Trastuzumab, which is used to treat certain HER2-positive breast and gastric cancers. This is the second biosimilar submission developed by the partnership that has been accepted for review in Europe."/>
Mylan and Biocon Announce Regulatory Submission for Proposed Biosimilar Trastuzumab Accepted for Review by European Medicines Agency
SCYNEXIS revealed on Wednesday the receipt of the orphan drug designation from the US Food and Drug Administration has for the novel triterpenoid broad-spectrum antifungal agent, SCY-078, for the treatment of invasive Aspergillus infections. Invasive aspergillosis is a serious fungal infection caused by Aspergillus species that usually affects people who have weakened immune systems, such as people who have had an organ transplant or a stem..."/>
SCYNEXIS passes US FDA orphan drug designation for SCY-078 for invasive aspergillus infections
Mylan NV. The anger over a 400 percent increase in EpiPen's price in the last nine years renewed simmering resentment over the relocation of the company's corporate address to a foreign country to lower its taxes and about CEO Heather Bresch's compensation,..."/>
Firestorm grows over price hikes on EpiPen [The Pittsburgh Tribune-Review]
Innovus Pharmaceuticals' FlutiCare™ in the nasal allergy market following the recent approval of Bayer AG's ClariSpray™. Bayer AG expanded its allergy portfolio in the United States to include ClariSpray™, a 24- hour nasal spray to treat allergy symptoms, in..."/>
SECFilings.com: Bayer's ClariSpray Success Bodes Well for Innovus Pharmaceuticals' FlutiCare
Mallinckrodt revealed on Wednesday the launch of a definitive agreement to divest its Nuclear Imaging business for about USD690m before tax impacts, including up-front and contingent consideration and the assumption of long-term obligations, to IBA Molecular. Mallinckrodt added that the total consideration of approximately USD690m consists of approximately USD574m of up-front consideration, the assumption of approximately USD39m of..."/>
Mallinckrodt to sell USD690m Nuclear Imaging business
Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions today announced that researchers will present scientific data at PAINWeek 2016 on September 8 in Las Vegas. Four presentations will be on abuse-deterrent product candidate ARYMO™ ER Extended-Release Tablets; one presentation will address..."/>
Egalet Announces Scientific Presentations at PAINWeek 2016 Meeting

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Consumer Discretionary653 Articles
Information Technology595 Articles
Financials484 Articles
Health Care338 Articles
Industrials322 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.